Comparative Pharmacology
Head-to-head clinical analysis: TROSPIUM CHLORIDE versus VESICARE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TROSPIUM CHLORIDE versus VESICARE.
TROSPIUM CHLORIDE vs VESICARE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tropium chloride is a quaternary ammonium compound that acts as a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3), thereby reducing smooth muscle tone in the bladder, decreasing detrusor overactivity, and increasing bladder capacity.
Competitive antagonist at muscarinic acetylcholine receptors (M1-M5), with selectivity for M3 receptors over M2. Inhibits bladder detrusor muscle contraction, increasing bladder capacity and reducing urinary urgency.
20 mg orally twice daily, extended-release 60 mg orally once daily in the morning.
5 mg orally once daily; may increase to 10 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (mean 14 hours); clinical context: supports twice-daily dosing
Terminal elimination half-life is approximately 45 hours (range 33–57 hours), supporting once-daily dosing.
Renal: 65% (40% unchanged, 25% as metabolites); Fecal/Biliary: 35% (primarily via bile)
Approximately 70% of an oral dose is excreted in urine (mainly as metabolites, <15% unchanged) and 25% in feces.
Category A/B
Category C
Anticholinergic
Anticholinergic